Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Current Deferred Revenue (2021 - 2025)

Historic Current Deferred Revenue for Roivant Sciences (ROIV) over the last 5 years, with Q1 2025 value amounting to $1.2 million.

  • Roivant Sciences' Current Deferred Revenue fell 7197.7% to $1.2 million in Q1 2025 from the same period last year, while for Mar 2025 it was $1.2 million, marking a year-over-year decrease of 7197.7%. This contributed to the annual value of $1.2 million for FY2025, which is 7197.7% down from last year.
  • Latest data reveals that Roivant Sciences reported Current Deferred Revenue of $1.2 million as of Q1 2025, which was down 7197.7% from $3.0 million recorded in Q4 2024.
  • In the past 5 years, Roivant Sciences' Current Deferred Revenue ranged from a high of $12.4 million in Q1 2023 and a low of $1.2 million during Q1 2025
  • For the 5-year period, Roivant Sciences' Current Deferred Revenue averaged around $6.4 million, with its median value being $5.9 million (2021).
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first skyrocketed by 7146.0% in 2022, then crashed by 7483.21% in 2024.
  • Roivant Sciences' Current Deferred Revenue (Quarter) stood at $5.9 million in 2021, then soared by 31.73% to $7.8 million in 2022, then plummeted by 39.78% to $4.7 million in 2023, then crashed by 35.31% to $3.0 million in 2024, then crashed by 61.54% to $1.2 million in 2025.
  • Its last three reported values are $1.2 million in Q1 2025, $3.0 million for Q4 2024, and $3.4 million during Q3 2024.